α4 integrin blockade impairs CD8 T cell neuroimmune surveillance following SIV infection
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci198730 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Pabitra B Pal und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Simian Acquired Immunodeficiency Syndrome, Simian Immunodeficiency Virus, Integrin alpha4. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH.
Abstract (Originalsprache)
Integrin-targeted therapies are under investigation for HIV-associated neuroinflammation, yet their effect on CNS antiviral immunity remains undefined. We examined the role of α4 integrin in T cell-mediated neuroimmune surveillance using SIV-infected macaques with α4 blockade and T cell-specific α4-deficient mice. In macaques, α4 blockade preserved CD4+ Th1 cell access to the brain parenchyma but impaired CD8 effector recruitment, disrupting antiviral control. Despite stable cerebrospinal fluid viral loads, hippocampal SIV RNA increased under blockade. Single-cell analyses revealed α4 enrichment in CD8 effector memory (Tem) cells; blockade reduced inferred CD8+ Tem-monocyte interactions and heightened innate immune activation in the hippocampus. Microscopy demonstrated persistent SIV-induced microglial simplification despite treatment. Th1 CD4 effectors correlated positively with gray matter viral RNA, whereas α4β7+ CD8+ T cells correlated inversely, implicating impaired CD8+ Tem recruitment in elevated parenchymal viral burden. In mice, α4 proved dispensable for CD4 trafficking to inflamed brain but essential for CD8 effector access across CNS compartments and for both subsets to reach skull marrow. These findings establish that α4 integrin governs CD8-mediated neuroimmune surveillance through coordinated cellular positioning, with blockade enabling viral seeding while disrupting spatially organized antiviral defense.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- California National Primate Research Center, University of California, Davis, Davis, California, USA.
- Organ Pathobiology and Therapeutics Institute and.
- Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Bruker Spatial Biology, Seattle, Washington, USA.
- Department of Pediatrics, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Förderung
- NIH
Zitieren
APA
Pal, P. B., Elizaldi, S. R., Diniz, G. B., Rai, R. P., Shaan Lakshmanappa, Y., Verma, A., Rossmiller, D., Kaufman, J., Srivastava, R., Ott, S., Erices, C. T., Schwartz, K., Beckman, D., Ma, Z. M., Petkov, A., Newhouse, D., Rajasundaram, D., Morrison, J. H., Raeman, R., & Iyer, S. S. (2026). α4 integrin blockade impairs CD8 T cell neuroimmune surveillance following SIV infection. Journal of Clinical Investigation. https://doi.org/10.1172/jci198730
Vancouver
Pal PB, Elizaldi SR, Diniz GB, Rai RP, Shaan Lakshmanappa Y, Verma A, et al. α4 integrin blockade impairs CD8 T cell neuroimmune surveillance following SIV infection. Journal of Clinical Investigation. 2026. doi:10.1172/jci198730
BibTeX
@article{Pal2026,
author = {Pal, Pabitra B and Elizaldi, Sonny R and Diniz, Giovanne B and Rai, Ravi Prakash and Shaan Lakshmanappa, Yashavanth and Verma, Anil and Rossmiller, Daniel and Kaufman, Jesse and Srivastava, Rahul and Ott, Sean and Erices, Carissa T and Schwartz, Kayla and Beckman, Danielle and Ma, Zhong-Min and Petkov, Alex and Newhouse, Daniel and Rajasundaram, Dhivyaa and Morrison, John H and Raeman, Reben and Iyer, Smita S},
title = {α4 integrin blockade impairs CD8 T cell neuroimmune surveillance following SIV infection},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci198730}
}
EUVIMED